Prostate CancerCLIQQCNCT07484971
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
An observational study of Prostate Cancer and Prostate Cancer (Diagnosis), run by Société Algérienne de Formation et Recherche en Oncologie at 24 sites in Algeria.
Trial summary
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria. Read more about this study
- Who is it for?
- Ages 19 years and older, men only
- Conditions the study is for
- Prostate Cancer, Prostate Cancer (Diagnosis), Prostate Cancer (Post Prostatectomy)
- How many people
- 2,000 participants
- Where
- 24 sitesAlgeria
- Study dates
- 21 Jul 2025to 21 Jul 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Patients with histologically and/or biologically confirmed prostate cancer, followed in the participating centers.
Who may be able to join
- Patients aged 19 years and older.
- Diagnosis of prostate cancer confirmed histologically and/or biologically.
- Patients followed in the participating oncology departments.
- Written informed consent obtained.
- Non Inclusion Criteria:
- Histological types other than carcinoma
- Secondary tumors
- Participation in an interventional study
Who cannot join
None listed.
Trial locations and contacts
24 sites in 1 country. Contact the study team or a site near you to ask about taking part.
24 sites in 1 country
Algeria24 sites, 24 recruiting
- Not yet recruiting
CAC Adrar - Oncology Department
Adrar, Algeria, 01000
KOUIDER KHADIDJA, Professor, +213 49 36 89 00, contact@esclinicalresearch.com
- Not yet recruiting
CAC Adrar - Radiotherapy Department
Adrar, Algeria, 01000
FELLAG Houmem, Doctor, +213 49 36 89 00, contact@esclinicalresearch.com
- Recruiting
CAC BLIDA - Oncology Department
Algiers, Algeria, 16000
BOUNEDJAR Adda, Professor, +213 25 20 90 72, contact@esclinicalresearch.com
- Recruiting
Centre Pierre et Marie Curie - Oncology Department
Algiers, Algeria, 16000
KEBOUA ESMA, Professor, +213 23 55 96 80, contact@esclinicalresearch.com
- Recruiting
Centre Pierre et Marie Curie - Radiology Department
Algiers, Algeria, 16000
OUKRIF Séam, Professor, +213 23 55 96 80, contact@esclinicalresearch.com
- Recruiting
CHU Bab El Oued
Algiers, Algeria, 16000
BELKACEM-NACER Abdelwahab, Professor, +213 21 96 06 06, contact@esclinicalresearch.com
- Recruiting
CHU Béni Messous - Oncology Departement
Algiers, Algeria, 16000
Oukkal Mohammed, Professor, +213 219 311 90, contact@esclinicalresearch.com
- Recruiting
EPH ROUIBA - Oncology Department
Algiers, Algeria, 16000
MAHFOUF Hassen, Professor, +213 21 86 04 35, contact@esclinicalresearch.com
- Recruiting
CAC Annaba - Oncology Departement
Annaba, Algeria, 23000
DJEDDI Hanene, Professor, +213 38 40 00 04, contact@esclinicalresearch.com
- Recruiting
CAC Annaba - Radiotherapy Department
Annaba, Algeria, 23000
NAOUN Lilia, Professor, +213 38 40 00 04, contact@esclinicalresearch.com
- Recruiting
CAC Annaba - Urology Departement
Annaba, Algeria, 23000
CHETTIBI kheireddine, Professor, +213 38 40 00 04, contact@esclinicalresearch.com
- Recruiting
CAC Bida - Radiotherapy Department
Blida, Algeria, 09000
HAOUI Messaouda, Professor, +213 25 20 90 72, contact@esclinicalresearch.com
- Recruiting
CAC BLIDA - Urology Department
Blida, Algeria, 09000
OULD ARBI Sid Ahmed, Professor, +213 25 20 90 72, contact@esclinicalresearch.com
- Recruiting
CHU Constantine - Oncology Departement
Constantine, Algeria, 25000
ZERROUK DALAL, Professor, +213 31 88 66 22, contact@esclinicalresearch.com
- Recruiting
EH Constantine - Oncology Departement
Constantine, Algeria, 25000
BENSALEM Assia, Professor, +213 31 88 66 22, contact@esclinicalresearch.com
- Recruiting
EPH Mostaghanem - Oncology Department
Mostaganem, Algeria, 27000
ZIDANE Habib, Professor, +213 45 41 09 49, contact@esclinicalresearch.com
- Recruiting
CAC ORAN - Oncology Department
Oran, Algeria, 31000
LARBAOUI Blaha, Professor, +213 20 33 91 20, contact@esclinicalresearch.com
- Recruiting
CAC ORAN - Radiotherapy Department
Oran, Algeria, 31000
BOUKERCHE Abdelbaki, Professor, +213 20 33 91 20, contact@esclinicalresearch.com
- Not yet recruiting
EHU ORAN - Oncology Department
Oran, Algeria, 31000
BEREKSI REGUIG FAIZA, Professor, +213 41 70 50 92, contact@esclinicalresearch.com
- Recruiting
EHU ORAN - Urology Department
Oran, Algeria, 31000
YOUSFI Mostafa Jamel, Professor, +213 41 70 50 92, contact@esclinicalresearch.com
- Recruiting
CAC Sétif - Oncology Departement
Sétif, Algeria, 19000
DIB Adlane Husseine, Professor, +213 36 45 45 45, contact@esclinicalresearch.com
- Recruiting
CAC Sétif - Radiotherapy Department
Sétif, Algeria, 19000
BOUDAOUD Khadidja, Professor, +213 36 45 45 45, contact@esclinicalresearch.com
- Recruiting
EPH Sidi Ghilès - Oncology Department
Tipasa, Algeria, 42000
SEGHIER Fatma, Professor, +213 24 33 12 25, contact@esclinicalresearch.com
- Recruiting
CAC Draa Ben Khedda - Radiotherapy Departement
Tizi Ouzou, Algeria, 15000
BENZIDANE Kahina, Professor, +213 549 30 70 71, contact@esclinicalresearch.com
About this study
The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer.
It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.
Read the detailed description
This is a descriptive, cross-sectional clinical study including patients with histologically and/or biologically confirmed prostate cancer who are being followed in the participating centers. This study planned to enroll 500 patients.
Data will be collected from medical records and structured patient interviews (≈30 minutes). A standardized electronic case report form (eCRF) will be used to ensure completeness and reliability of the data. The variables studied will include sociodemographic data, medical history, clinical and biological characteristics of the disease, diagnostic examinations performed, and the therapeutic strategies implemented. All information will be anonymized and used exclusively for research purposes.
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), Prostate Cancer (Post Prostatectomy), Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer Metastatic, Prostate Cancer (Adenocarcinoma)
- Keywords
- oncology, patient outcome, Prostate Cancer, Prostate Cancer in Algerian patients, Observational Study, Retrospective data, Treatment strategies, Diagnostic approaches, Clinical characteristics, Epidemiological data, Demographic data, Cross-sectional study, Real-world data, Algeria, Algerian Study
- Medical subject headings
- Prostatic Neoplasms, Disease, Adenocarcinoma, Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Socio-demographic characteristics of patients with prostate cancer in Algeria
Frequency (%) of sociodemographic characteristics of patients with prostate cancer in Algeria, including age at diagnosis, marital status, and socioeconomic level.
Measured: At Baseline ( Initial visit )
Personal and family history of cancer
Frequency (%) of patients with personal and family history of cancer.
Measured: At Baseline (Initial Visit)
Environmental and occupational exposures
Frequency (%) of patients with environmental or occupational exposures.
Measured: At Baseline (Initial visit)
Smoking history
Frequency (%) of patients according to smoking status (current, former, never).
Measured: At Baseline (Initial visit)
Alcohol consumption
Frequency (%) of patients according to alcohol consumption (yes/no).
Measured: At Baseline (Initial visit)
Initial symptoms and circumstances of diagnosis
Frequency (%) of patients according to type of initial symptoms and circumstances of diagnosis.
Measured: At Baseline (Initial visit)
International Prostate Symptom Score (IPSS)
Distribution of patients according to the International Prostate Symptom Score (IPSS) at baseline. The IPSS is a validated questionnaire assessing the severity of lower urinary tract symptoms, with a total score ranging from 0 to 35, where higher scores indicate more severe (worse) symptoms.
Measured: At Baseline (Initial visit)
Evolutionary status of patients
Frequency (%) of patients according to disease status (in remission or with disease progression).
Measured: At Baseline (Initial visit)
Secondary outcomes (13)
Diagnosis by PSA testing
% of patients diagnosed by PSA testing.
Measured: At Baseline (Initial visit)
Diagnosis by imaging
% of patients diagnosed by imaging.
Measured: At Baseline (Initial visit)
Diagnosis by biopsy
% of patients diagnosed by biopsy.
Measured: At Baseline (Initial visit)
Time from symptom onset to first medical consultation
Median time (in days) between onset of first symptoms and first medical consultation.
Measured: At Baseline (Initial visit)
Time from first consultation to confirmed diagnosis
Median time (in days) between first medical consultation and confirmed diagnosis.
Measured: At Baseline (Initial visit)
Patients discussed in multidisciplinary team meetings
% of patients discussed in tumor boards / multidisciplinary team meetings.
Measured: At Baseline (Initial visit)
Initial treatment: Surgery
% of patients receiving surgery as initial treatment.
Measured: At Baseline (Initial visit)
Initial treatment: Radiotherapy
% of patients receiving radiotherapy as initial treatment.
Measured: At Baseline (Initial visit)
Initial treatment: Hormone therapy
% of patients receiving hormone therapy as initial treatment.
Measured: At Baseline (Initial visit)
Initial treatment: Active surveillance
% of patients under active surveillance as initial management.
Measured: At Baseline (Initial visit)
Time from diagnosis to treatment initiation
Median time (in days) between diagnosis and treatment initiation.
Measured: At Baseline (Initial visit)
Specialty of physician initiating treatment
Medical specialty of the physician initiating treatment (urologist, oncologist, etc.).
Measured: At Baseline (Initial visit)
Adverse events
Frequency of adverse events by system/organ class and distribution according to severity grades (CTCAE grades 1 to 5).
Measured: At Baseline (Initial visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2026
- Study start21 Jul 2025
- Primary completion21 Jul 2026 (estimated)
- Study completion21 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Société Algérienne de Formation et Recherche en Oncologie
- Sponsor type
- University, hospital or other
- Collaborators
- ES Clinical Research, Ipsen, Astellas Pharma Inc
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07484971
- Sponsor's protocol ID
- SAFRO 02.002
- Acronym
- CLIQQC
- Status last verified
- Feb 2026
- First submitted
- 4 Sep 2025
- Last updated
- 17 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No